Methods for treating cancer using prostate specific antigen and tumor endothelial marker peptides
View Patent ↗The present invention is directed to prostate specific antigen (PSA) and tumor endothelial marker 8 (TEM8) peptide compositions and methods for treating cancer with the compositions.
1. A composition for treating cancer comprising:
(i) a pharmaceutically acceptable carrier,
(ii) prostate specific antigen (PSA) peptide PSA 146-154 (SEQ ID NO: 3), and
(iii) PSA peptide PSA 154-173 (SEQ ID NO: 1), PSA peptide PSA 210-230 (SEQ ID NO: 2), tumor endothelial marker 8 (TEM8) peptide TEM8 298-306 (SEQ ID NO: 18), or combinations thereof.
2. The composition of claim 1 further comprising granulocyte macrophage colony stimulating factor (GM-CSF).
3. The composition of claim 1 further comprising a Toll-Like Receptor 9 (TLR9) agonist, an inhibitor of Cytotoxic T-Lymphocyte Antigen 4 (CTLA4), or an inhibitor of Programmed Death-1 (PD-1).
4. The composition of claim 3 wherein the TLR9 agonist is a CpG-oligodeoxynucleotide (CpG-ODN).
5. The composition of claim 3 wherein the inhibitor of CTLA4 is a monoclonal antibody.
6. The composition of claim 3 wherein the inhibitor of PD-1 is a monoclonal antibody.
7. A kit comprising a composition, instructions for administration of the composition for treating cancer, and a device for administering the composition to a patient, wherein the composition comprises:
(i) a pharmaceutically acceptable carrier,
(ii) prostate specific antigen (PSA) peptide PSA 146-154 (SEQ ID NO: 3), and
(iii) PSA peptide PSA 154-173 (SEQ ID NO: 1), PSA peptide PSA 210-230 (SEQ ID NO: 2), tumor endothelial marker 8 (TEM8) peptide TEM8 298-306 (SEQ ID NO: 18), or combinations thereof.
8. The kit of claim 7 further comprising granulocyte macrophage colony stimulating factor (GM-CSF).
9. The kit of claim 7 further comprising a Toll-Like Receptor 9 (TLR9) agonist, an inhibitor of Cytotoxic T-Lymphocyte Antigen 4 (CTLA4), or an inhibitor of Programmed Death-1 (PD-1).
10. The kit of claim 9 wherein the TLR9 agonist is a CpG-oligodeoxynucleotide (CpG-ODN).
11. The kit of claim 9 wherein the inhibitor of CTLA4 is a monoclonal antibody.
12. The kit of claim 9 wherein the inhibitor of PD-1 is a monoclonal antibody.
13. A method of treating prostate cancer comprising administering to a patient in need thereof an effective amount of peptides comprising:
(i) prostate specific antigen (PSA) peptide PSA 146-154 (SEQ ID NO: 3), and
(ii) PSA peptide PSA 154-173 (SEQ ID NO: 1), PSA peptide PSA 210-230 (SEQ ID NO: 2), tumor endothelial marker 8 (TEM8) peptide TEM8 298-306 (SEQ ID NO: 18), or combinations thereof.
14. The method of claim 13 further comprising administering to the patient granulocyte macrophage colony stimulating factor (GM-CSF).
15. The method of claim 13 or claim 14 further comprising administering to the patient a Toll-Like Receptor 9 (TLR9) agonist, an inhibitor of Cytotoxic T-Lymphocyte Antigen 4 (CTLA4), or an inhibitor of Programmed Death-1 (PD-1).
16. The method of claim 15 wherein the TLR9 agonist is a CpG-oligodeoxynucleotide (CpG-ODN).
17. The method of claim 15 wherein the inhibitor of CTLA4 is a monoclonal antibody.
18. The method of claim 15 wherein the inhibitor of PD-1 is a monoclonal antibody.